The Primary Objective of the Trial is to Evaluate the Effect of the Addition of Belantamab Mafodotin to Standard of Care Therapy on the Titres of Serum Anti-dsDNA Antibodies in Patients With Previously Treated SLE.

The primary objective of the trial is to evaluate the effect of the addition of belantamab mafodotin to standard of care therapy on the titres of serum anti-dsDNA antibodies in patients with previously treated SLE. Estimand for Primary Endpoint: Change of serum anti-dsDNA antibody titers at 24 weeks of treatment vs baseline.